CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Cowen
About InfinityInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:Jaren Irene Madden, Senior Director, Investor Relations and Corporate Communications617-453-1336 or [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infinity-to-present-at-37th-annual-cowen-and-company-healthcare-conference-300413327.html
SOURCE Infinity Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All